Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.

Shadi ChamseddineMichael LaPelusaLianchun XiaoYehia I MohamedSunyoung S LeeZishuo Ian HuRikita I HatiaManal HassanJames C YaoDan G DudaSaumil DatarHesham M AminAhmed O Kaseb

Published in: Journal of hepatocellular carcinoma (2024)

Plasma GH is a prognostic biomarker in patients with advanced HCC treated with D+T. Given the relatively small patient cohort size, this finding should be further validated in larger randomized clinical trials in advanced HCC patients.

Keyphrases

growth hormone
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
peritoneal dialysis
case report
patient reported outcomes